ÿþ<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"> <html> <head> <meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1"> <title>EASL 2010 - Poster Presentations</title> <link rel="stylesheet" type="text/css" href="style.css"> </head> <body> <table width="750" align="center" border="0" cellspacing="0" cellpadding="0" class="MainTable"> <tr> <td><img src="http://www2.kenes.com/liver-congress/PublishingImages/top_ei.jpg" width="760" height="129" /></td> </tr> <tr> <td class="content"><h1>Poster Presentations</h1> <P><b>Session Title:</b> Category 8c. ALCOHOLIC DRUG INDUCED AND FATTY LIVER DISEASE: c. NASH/NAFLD - CLINICAL<br><b>Presentation Date:</b> Apr 15, 2010</P><h2 align='left'><B>DIAGNOSTIC VALUE OF LIVER INJURY BIOMARKERS, FIBROTEST (FT), STEATOTEST (ST), NASHTEST (NT) IN PATIENTS WITHOUT ADVANCED DISEASE UNDERGOING BARIATRIC SURGERY</B></h2> <p align='left'><b>A. Hollebecque</b><sup>1</sup>*, M. Munteanu<sup>2</sup>, L. Arnalsteen<sup>3</sup>, D. Buob<sup>4</sup>, E. Leteurtre<sup>4</sup>, R. Caiazzo<sup>3</sup>, S. Dharancy<sup>1</sup>, T. Poynard<sup>5</sup>, V. Ratziu<sup>5</sup>, F. Pattou<sup>3</sup>, P. Mathurin<sup>1</sup><br> <em><sup>1</sup>Maladies de l'Appareil Digestif, Hôpital Huriez, Lille, <sup>2</sup>Société BioPredictive, Paris, <sup>3</sup>Service de Chirurgie Digestive et Endocrinienne, Hôpital Huriez, <sup>4</sup>Service d'Anatomie Pathologique, CHU de Lille, Lille, <sup>5</sup>Service d'Hépato-Gastroentérologie, Hôpital de la Pitié-Salpétrière, Paris, France. *philippe.mathurin@chru-lille.fr</em></p><br> <p align='justify'>In a prospective study using liver biopsy we observed in a significant decrease in percentage of patients with steatosis and NAFLD score (NAS) at one year and the percentage of patients with probable or definite NASH at 5 years after bariatric surgery in 381 patients with severe obesity.<br><b><b>Aim: </b></b> Here we assess <br>1) the diagnostic values of biomarkers (FT, ST, NT) and <br>2) the impact of bariatric surgery at 1 year using biomarkers.<br><b><b>Patients and methods: </b> </b>For 1) 53 patients of the previous study had biopsy (NAS score, Brunt fibrosis scoring system) and biomarkers 5 years after surgery. For 2) 82 new patients prospectively included had repeated biomarkers at baseline and 1 year after surgery (Y1). FT, ST, NT were blindly analyzed according to manufacturer recommendations and using standard predefined cutoffs. Characteristics of patients before and after surgery were similar for these 2 groups: 25% males, mean age 40 vs 42 years, BMI(kg/m2) 48.5 (0.9) vs 49.2 (0.8) at baseline and 37.6 (0.9) vs 38.0 (1.0) at one year.<br><b><b>Results: </b></b> <br>1) Among the 53 pts, the AUROC for F234 was 0.84 (95%CI 0.48-0.96 P=0.001); the AUROC of ST for S234 was 0.83 (95%CI 0.59-0.94, P< 0.0001). For the diagnosis of Borderline NASH, NT and biopsy were concordant in 41/53 (77%) cases.<br>2) Among the 82 patients, FT was interpretable in 99% (81/82). In 1 patient a hemolysis was suspected with low haptoglobin. <br>At baseline 2/81 (2.5%) patients had bridging fibrosis, 56/74 (75.7%) steatosis >5% and 64/74 (86.5%) possible NASH. One year after surgery, 1/81 (1.2%) patients had bridging fibrosis, 31/74 (41.9%) steatosis >5% and 54/74 (72.9%) possible NASH. Mean FT decreased significantly: 0.12 (0.01) vs 0.10 (0.01), p=0.02; 8 pts improved FT >=0.10, all being lesser than 0.20. Mean ST decreased significantly: 0.55 (0.02) vs 0.35(0.02), p< 0.0001; 39 patients improved ST >=0.20.<br><b><b>Conclusions: </b></b> This study validated the diagnostic value of FT, ST and NT in obese patients undergoing bariatric surgery, suggesting non-invasive alternatives to biopsy for inclusion and follow-up.</p> <br><a href='Session-P01-8c.htm'>Back</a><br> <p>&nbsp;</p> <p>&nbsp;</p></td> </tr> </table> </body> </html>